Comparative Efficacy of Biologic Therapies for Enthesitis, Dactylitis, and ACR50 in Psoriatic Arthritis: A Network Meta-Analysis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #384; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Risankizumab ranked last (RR 1.33, 1.11-1.59). Biologic efficacy in PsA varies considerably by outcome domain. IL-17 inhibitors lead for enthesitis, with five-dose secukinumab loading offering the clearest advantage, while ixekizumab was top-ranked for dactylitis. Adalimumab demonstrated meaningful outcome-specific activity, competitive for dactylitis and ACR50 but falling short for enthesitis."
Retrospective data • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A
|
|
KRIMA PATEL 1; Urvi zala 2; Shivam Patel 3; SHILPA RAMAN DANAGARA 4; Parkash Bachani 1; Anubhav Singh 5; and Ahmad Qurie 1
|